News
Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...
Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...
As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...
Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...
About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...
(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 ...
The intricate interplay between pancreatic beta cells and glucagon-like peptide-1 (GLP-1) has drawn considerable attention in efforts to improve the diagnosis and treatment of diabetes and ...
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists ...
According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results